SCOLR Pharma, Inc. (SCLR) [Rocket]

In millions, except per share items	Sep-30-11	Jun-30-11	Mar-31-11	Dec-31-10	Sep-30-10	Jun-30-10	Mar-31-10	Dec-31-09
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Cash flows from operating activities:
Net loss	-2.5	-2.7			-2.5	-1.5
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization	0.2	0.2			0.2	0.1
Write-off of intangible assets and capital assets	0.0
Interest expense	0.2
Unrealized gain on fair value of warrant		0.0			0.1	0.0
Share-based compensation for employee services	0.2	0.2			0.2	0.1
Gain on sale of equipment and furniture	-0.2	-0.1
Increase (decrease) in cash resulting from changes in assets and liabilities
Accounts receivable	0.1	0.1			0.1	0.1
Inventory	-0.1	-0.1			-0.1
Prepaid expenses and other current assets	-0.3	-0.2			-0.2	-0.2
Accounts payable and accrued expenses	-0.4	-0.3			-0.3	-0.2
Net cash used in operating activities	-2.9	-3.2			-2.4	-1.5

Cash flows from investing activities:
Purchase of equipment and furniture	0.0	0.0			0.0	0.0
Proceeds from sale of equipment and furniture	0.2	0.2
Patent and technology rights payments	0.0	0.0			-0.3	-0.2
Restricted cash		0.4			0.2	0.1
Net cash provided (used) by investing activities	0.4	0.5			-0.1	-0.2

Cash flows from financing activities:
Proceeds from issuance of convertible debentures		1.2
Net cash provided by financing activities		1.2				3.8
Net (decrease) increase in cash	-1.2	-1.5			1.3	2.1
Cash at beginning of period		1.9				1.2
Cash at end of period	0.6	0.4			2.4	3.3

Supplemental disclosure of non-cash investing and financing activities:
Issuance of warrants in connection with convertible debt offering		0.1
Beneficial conversion feature		0.7